Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 20 | ECE2009 | Next issue

11th European Congress of Endocrinology


Thyroid cancer

ea0020s20.1 | Thyroid cancer | ECE2009

C Cell neoplasia

Elisei Rossella

Parafollicular C-Cells represent 1% of thyroid cells and differ from follicular cells for their origin from the neural crest. At variance with follicular cells, their growth and function are independent from thyrotropin stimulating hormone (TSH), they do not take up iodine and they produce and secrete calcitonin (CT) but not thyroglobulin. C-Cell Hyperplasia (CCH) is defined as an increased number of normal C-cells (i.e. 50 or more C-cells in at least one low-power field (100&...

ea0020s20.2 | Thyroid cancer | ECE2009

Ultrasound diagnosis and follow-up of thyroid cancer

Erdogan Murat

Utlrasonography is now a crucial part of diagnosis and the follow-up of thyroid cancers as well as other thyroid disorders. If you are an endocrinologist of the age 40 or below and if you still do not perform ultrasonography by yourself, we believe you have an important skill to learn, which will guide you through out your thyroid practice and totally change your vision to thyroid disorders.We hereby discuss the importance of thyroid ultrasonography for ...

ea0020s20.3 | Thyroid cancer | ECE2009

Advances in management of thyroid cancer with novel chemotherapy agents

Nutting Christopher

Recently there has been resurgence in interest in the treatment of iodine negative differentiated thyroid cancer and medullary thyroid cancer with novel agents.This presentation will review the recent literature on treatment of thyroid cancers with multi-targeted tyrosine kinase inhibitors. Data on the experience of the Royal Marsden Hospital with Sorafenib will be presented. Vascular endothelial growth factor inhibition appears to be a particularly impo...

ea0020s20.4 | Thyroid cancer | ECE2009

Pregnancy after exposure to radioiodine

Hyer Steve

The administration of 131I should strictly be avoided in pregnancy. Iodide concentrating capacity can be detected in the thyroid of the 10–11 week fetus. If administration is within the first 8 weeks, the major problem is fetal whole body dose due to gamma emission from 131I in the maternal bladder (about 50–100 μGy/ MBq of administered activity). This dose is reduced if the mother is well hydrated and voids frequently. Generally the lifeti...